NEJM Knowledge+ Pediatrics Board Review CME

Activity description

  • Purpose: To promote the professional development of pediatric clinicians.
  • Educational objectives
    • Demonstrate an increase in your knowledge of pediatric medicine.
    • Evaluate the appropriateness of clinical information as it applies to the care of your patients.
    • Demonstrate an improvement in your ability to make decisions that provide safe and effective medical care.
    • Recognize areas of personal strength and areas for growth in clinical knowledge.
  • Target audience: Physicians and residents who are seeking to maintain and augment their knowledge in pediatric medicine and/or preparing for their initial board certification or recertification.
  • Funding source: None
  • Content: CME content is developed by a team of physician authors and editors in a standardized process that includes multi-stage peer review. The research sources that are used include updated best practice guidelines and expert recommendations, are adherent to accepted standards of scientific evidence, and are fully referenced. Content is free of commercial bias and adheres to the ACCME’s Standards for Integrity and Independence in Accredited Continuing Education.
  • Activity type: Enduring material
  • Method of participation
    • You must answer questions correctly to receive AMA PRA Category 1 Credits™ and ABP MOC points toward Certification Maintenance.
    • Six questions answered correctly are designated for 1 AMA PRA Category 1 Credit™ and 1 ABP MOC point.

Accreditation statements

AMBOSS is accredited by the Accreditation Council for Continuing Medical Education (ACCME®) as a provider of continuing medical education (CME) for physicians.  

  • American Medical Association: AMBOSS designates this Internet point-of-care activity for a maximum of 0.5 AMA PRA Category 1 Credit(s)™. Physicians should claim only credit commensurate with the extent of their participation in the activity.
  • American Board of Pediatrics (ABP) Maintenance of Certification Program: Successful completion of this CME activity, which includes participation in the evaluation component, enables the learner to earn up to 0.5 MOC points in the American Board of Pediatrics’ (ABP) Maintenance of Certification (MOC) program. It is the CME activity provider’s responsibility to submit learner completion information to ACCME for the purpose of granting ABP MOC credit.

Accreditation term

This activity was initially developed by the Massachusetts Medical Society in 2017, and acquired by AMBOSS in April 2024. 

  • Original Release Date: February 1, 2017
  • Review dates: 2018, 2019, 2020, 2021, 2022, 2023, 2024
  • Termination Date: February 1, 2025

Financial disclosures

This activity was initially developed by the Massachusetts Medical Society in 2017, and acquired by AMBOSS in March 2024. There are no current AMBOSS contributors to this content. 

Massachusetts Medical Society (NEJM Knowledge+) contributors
Below are all relevant financial relationships reported by NEJM Knowledge+ contributors from 2020-2023.

Vaneeta Bamba, MD
: Novo Nordisk, Growth Advisory Board for Genetic Short Stature, discontinued Nov 2020
2022: Nothing disclosed
2023: Nothing disclosed

Ethan Brown, MD
: Rune Labs, consultant, discontinued Apr 2019
2022: Rune Labs, consultant
2023: Nothing disclosed

Steven Chen, MD
:  Pfizer, advisory board member, discontinued May 2021 Novartis, advisory board member, discontinued Dec 2021

Ezra M. Cohen, MD
: Cornerstone Research Group, consultant
2022: Nothing disclosed
2023: Presidio, scientific board member

Nathan Connell, MD
:  Nothing disclosed
2022: Takeda Pharmaceutical, consultant
2023: Takeda Pharmaceutical, consultant Octapharma, honoraria Genentech, advisory board member Doximity, equity

Areeg H. El-Gharbawy, MD
: Ultragenyx, principal investigator for a clinical trial Ultragenyx, advisory board member Amicus, advisory board member

Rajesh T. Gandhi, MD
: Merck, scientific advisory board
2022: Nothing disclosed
2023: Nothing disclosed

Glenn J. Hanna, MD
: Actuate Therapeutics, grant/funding Bicara, consultant/advisory board Bicara, grant/funding Boxer Capital, consultant Bristol Myers Squibb, grant/funding Bristol Myers Squibb, consultant Coherus, consultant Elevar, consultant/advisory board Exicure, grant/funding, discontinued Jan 2022 Exicure, consultant/advisory board Gateway for Cancer Research, grant/funding Genentech, grant/funding General Catalyst, consultant GlaxoSmithKline, grant/funding ImmunityBio, grant/funding Kartos Therapeutics, grant/funding Kite Pharma, grant/funding, discontinued Jun 2022 KSQ Therapeutics, consultant KSQ Therapeutics, grant/funding Kura Oncology, consultant/advisory board Kura Oncology, grant/funding Merck, consultant/advisory board Naveris, consultant/advisory board Prelude, consultant/advisory board Rain Therapeutics, consultant, discontinued Nov 2021 Regeneron, consultant/advisory board Regeneron, grant/funding Remix Therapeutics, consultant/advisory board Repertoire, grant/funding Sanofi Genzyme, advisory board, discontinued Nov 2021 Sanofi Genzyme, grant/funding Secura Bio, grant/funding V Foundation, grant/funding, discontinued Jun 2022

Jonathan S. Hausmann, MD
: Pfizer, consultant, discontinued Dec 2020 Biogen, consultant, discontinued Dec 2020 Novartis, consultant
2022: Pfizer, consultant, discontinued Dec 2020 Biogen, consultant, discontinued Dec 2020 Novartis, consultant
2023: Fresenius Kabi, consultant Novartis, consultant

Brian C. Healy, MD
: Analysis Group, grant support Celgene (Bristol Myers Squibb), grant support Verily, grant support Novartis, grant support Merck Serono, grant support Genzyme, grant support
2022: Analysis Group, research support to institution, discontinued Nov 2020 Celgene (Bristol Myers Squibb), research support to institution, discontinued Nov 2020 Novartis, research support
2023: Novartis, research support

Koyal Jain, MD, MPH
: PI for Kaneka study and Visterra study

Mihir M. Kamdar, MD
: Amorsa Therapeutics, scientific advisory board, stockholder Medtronic, consultant, fees Fern Health, consultant, fees
2022: Nothing disclosed
2023: Elevate, cofounder and chief medical officer Fern Health, medical advisor

Ruslan Korets, MD
: Boston Scientific, consultant
2022: Boston Scientific, consultant
2023: Boston Scientific, consultant

Lekha M. Rao, MD
: Epigenyx Therapeutics, consultant UCB, principal investigator for a clinical trial Eisai, principal investigator for a clinical trial

Leigh C. Reardon, MD
: Janssen, speaker CareDx, participant in advisory board discussion, discontinued Dec 2020
2022: Janssen, advisory committee
2023: Janssen, consultant

Eric Roeland, MD
: Napo Pharmaceuticals, scientific advisory board Actimed Therapeutics, scientific advisory board Meter Health, scientific advisory board Veloxis Pharmaceuticals, consultant Aileron Therapeutics, consultant BYOMass, consultant Takeda, advisory board Enzychem Lifesciences Pharmaceutical Company, data safety monitoring board

Deborah R. Stein, MD
: Nothing disclosed
2022: Nothing disclosed
2023: Horizon, consultant Alexion, consultant

Joji Suzuki, MD
: Indivior, research support, discontinued Aug 2023

Taher S. Valika, MD
: Save My Scope Inc, chief medical officer

Ruth Ann Vleugels, MD, MPH, MBA
: Pfizer, principal investigator for a clinical trial

Raymond Y. Wang, MD
: Biomarin Pharmaceutical, speaking engagement, discontinued Jul 2019 Biomarin Pharmaceutical, advisory committee, discontinued Sep 2019 RegenxBio, advisory committee, discontinued May 2020 Takeda Pharmaceutical, advisory committee, discontinued Aug 2020 Ultragenyx Pharmaceutical, webinar, discontinued Nov 2020 Inventiva Pharmaceutical, advisory committee, discontinued Dec 2020 Neurogene, advisory committee, discontinued Nov 2020 Denali Therapeutics, drug monitoring committee
2022: Biomarin, ad hoc advisory board, discontinued Oct 2021 Orphazyme, ad hoc FDA advisory meeting, discontinued Oct 2021 Sio Gene Therapies, consultant, discontinued Nov 2021 Sio Gene Therapies, ad hoc advisory board, discontinued Aug 2021 Inventiva Pharmaceutical, ad hoc advisory board, discontinued Jul 2021 Takeda Pharmaceutical, ad hoc advisory board, discontinued Mar 2021 Ultragenyx, speaker, discontinued Nov 2020 Neurogene, ad hoc advisory board, discontinued Oct 2020 Regenxbio, ad hoc advisory board, discontinued Apr 2020
2023: RegenxBio, consultant Takeda Pharmaceutical, advisory committee, discontinued 2022 Denali, drug safety monitoring board

Sharmeel K. Wasan, MD
: Pfizer, grant support
2022:Nothing disclosed
2023: Nothing disclosed

All relevant financial relationships were mitigated prior to the beginning of this activity in accordance with ACCME and MMS policies. All other individuals in control of the content have reported no relevant financial relationships with ineligible companies for this activity. The complete list of contributors can be found here.

Redeeming credit

  1. Look for the CME widget on your AMBOSS dashboard. You will need to fill out your personal information by following the "Go to CME Credits" link. You can also access this by heading to Exams & CME > CME Credits in the sidebar menu.
    Screenshot 2024-03-27 at 10.33.52 AM.png
  2. Under your profile, you will see two tabs. In the “To claim” tab, you will see an entry with the total number of CME credits you have earned for board review questions.
    Click “Claim credits” at the bottom right. 

Before clicking “Claim credits”, please make sure that all of your profile information is correct.

  1. A pop-up box will appear with some brief post-activity evaluation questions. Answer the questions, and click “Submit.”
  1. The search entry will then disappear from the list in the “To claim” tab and will appear in the "Claimed" tab, with the date that it was claimed. You will see one of the following tags on the search entry: 
  • Submitted, if the credit was successfully submitted to the board listed in your profile
  • Rejected, if the credit was unsuccessfully submitted to the board listed in your profile
  • Not submitted, if there was no board listed in your profile.

You will also see an option to download a PDF that certifies your credit.

For questions or feedback related to the AMBOSS CME program, please email us at

Was this article helpful?

Articles in This Section